Unknown

Dataset Information

0

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.

ABSTRACT:

SUBMITTER: Tan S 

PROVIDER: S-EPMC5777972 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.

Tan Shuguang S   Liu Kefang K   Chai Yan Y   Zhang Catherine W-H CW   Gao Shan S   Gao George F GF   Qi Jianxun J  

Protein & cell 20180101 1

Similar Datasets

Unknown Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
| S-EPMC5789049 | biostudies-literature
Unknown Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
| S-EPMC7007418 | biostudies-literature
Unknown Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
| S-EPMC11022803 | biostudies-literature
Unknown Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
| S-EPMC5514103 | biostudies-literature
Unknown Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.
| S-EPMC5223223 | biostudies-literature
Unknown Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.
| S-EPMC5685743 | biostudies-literature
Unknown Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
| S-EPMC5925824 | biostudies-literature
Unknown PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
| S-EPMC4589506 | biostudies-literature
Unknown Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1.
| S-EPMC10315546 | biostudies-literature
Unknown High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.
| S-EPMC4955062 | biostudies-literature